# NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial

Study · id `cardio:ct-nct01303640` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01303640](<https://clinicaltrials.gov/study/NCT01303640>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01303640

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3235 participants.

## Technical summary

Registry record NCT01303640. Randomized; no masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2015-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 3235 participants (enrolled count; ClinicalTrials.gov record NCT01303640, source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01303640, source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)
- Primary completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01303640, source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)
- Completion: 2015-10 (actual) (ClinicalTrials.gov record NCT01303640, source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01303640, source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01303640-2015-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial
- Acronym: NEXT
- Condition: Coronary Artery Disease
- Intervention (Device): Biolimus-eluting stent
- Intervention (Device): Everolimus-eluting stent
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

## Provenance

Content hash: b1b855eaaa66cd796adc7b00bf39d36ca38878d690fab14f0b3d72ae74f7c6d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
